DEALS

Zhong Lun Advises on Ocumension Therapeutics’ IPO in Hong Kong

Release time：2020-07-10 Voice Announcements

On July 10, 2020, Ocumension Therapeutics (1477.HK) announced the closing of its initial public offering on the Main Board of the Stock Exchange of Hong Kong Limited, raising the net proceeds of approximately HK$1.424 billion prior to the exercise of the over-allotment option. Morgan Stanley and Goldman Sachs acted as joint sponsors for the offering.

Ocumension is a China-based ophthalmic pharmaceutical platform company dedicated to identifying, developing and commercializing first-or best-in-class ophthalmic therapies and has, in less than three years, built a strategically designed ophthalmic drug portfolio that is comprehensive, innovative and validated. Ocumension has 16 drug assets in its portfolio, covering all major front- and back-of-the-eye diseases, making it one of only a few pharmaceutical companies in China with such full coverage.

As Ocumension’s long-term legal counsel, Zhong Lun Law Firm had provided legal services for its incubation and inception, every round of financing and restructuring, and acted as its PRC legal advisor in this offering. The legal team of Zhong Lun for this offering was led by Anthony Zhao, Catherine Chen, William Jia, and Shaun Gao, and included Roy Zheng, Yun Hu and Lindsay Zhang etc.; in addition, Helen Cheng and Samuel Zhang advised on the IP-related matters, and Mark Gao and Hao Wu advised on the ESOP tax planning, during the IPO process.

中伦项目组和欧康维视生物CEO刘晔

Previous：Zhong Lun successfully secured the first unconditional anti-trust clearance on the merger filing involving VIE structure Next：Zhong Lun Advised on Ares’s Acquisition of SSG Capital

Print articles from Zhong Lun

Insights >

Publiciations >

Monthly Highlights >

Articles

Deals

Zhong Lun Assists MENA’s First QFII Asset Management Organization to Issue Chinese Securities Product

Zhong Lun Assists Yuan Kee Dumpling with First International Outlet Launch

Events

Awards

Zhong Lun Advises on Ocumension Therapeutics’ IPO in Hong Kong